Inte d Application No

		PCT/GB2	004/003236
A CLASSII IPC 7	FICATION OF SUBJECT MATTER C12Q1/68		
	·		*
According to	International Patent Classification (IPC) or to both national classific	ation and IPC	• •
	SEARCHED		
Minimum do	cumentation searched (classification system followed by classificati	on symbols)	
IPC 7	C12Q		
	·	<u> </u>	·
Documentat	tion searched other than minimum documentation to the extent that of	such documents are included in the flet	ds searched
		•	• • • • • • • • • • • • • • • • • • • •
Electronic da	ata base consulted during the international search (name of data ba	se and, where practical, search terms	used)
EPO-In	ternal, BIOSIS, WPI Data, EMBASE, Se	equence Search	• • • • • • • • • • • • • • • • • • • •
	·		
C. DOCUME	ENTS CONSIDERED TO BE RELEVANT		·
Category *	Citation of document, with indication, where appropriate, of the rel	evant passages	Relevant to claim No.
		<del></del>	1
X	NISHIZATO YOHEI ET AL: "Polymory	ohisms of	1,4-12,
	OATP-C (SLC21A6) and OAT3 (SLC22)	A8) genes:	15-21
	consequences for pravastatin pharmacokinetics."	. •	,
	CLINICAL PHARMACOLOGY AND THERAPI	EUTICS.	
	JUN 2003,	)6) nagas	
	vol. 73, no. 6, June 2003 (2003-0 554-565, XP002306135	, pages	!
	ISSN: 0009-9236		
,	cited in the application		0.030
Α			2,3,13,
.	abstract		• • • • • • • • • • • • • • • • • • • •
1	page 560, right-hand column - page 560	je 561	
Ì	page 562 — page 563 tables I—VI	,	
ĺ	·	-/ <del></del>	
			<u></u>
	er documents are listed in the continuation of box C.	χ Patent family members are its	sted in annex.
_	egories of cited documents :	"T" later document published after the or priority date and not in conflict	
conside	nt defining the general state of the art which is not ared to be of particular relevance	cited to understand the principle invention	
"E" earlier de filing de	ocument but published on or after the International ate	"X" document of particular relevance; cannot be considered novel or ce	the claimed invention
"L" document	nt which may throw doubts on priority claim(s) or s cited to establish the publication date of another	Involve an Inventive step when the	e document la taken alone
citation	or other special reason (as specified) nt referring to an oral disclosure, use, exhibition or	"Y" document of particular relevance; cannot be considered to involve document is combined with one	an inventive step when the
other m		ments, such combination being o	
later the	an the priority date claimed	"&" document member of the same pa	itent family
Date of the a	ctual completion of the international search	Date of mailing of the international	I search report
7	March 2005	0 4, 04, 200	5
Name and m	alling address of the ISA	Authorized officer	
	European Patent Office, P.B. 5818 Patentiaan 2 NL - 2280 HV Rijswijk		
	Tel. (+31-70) 340-2040, Tx. 31 651 epo ni, Fex: (+31-70) 340-3016	Madlener, M	

Intern al Application No PCT/GB2004/003236

	PCT/GB2004/003236	
	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	In the second se
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X .	TIRONA ROMMEL G ET AL: "Polymorphisms in OATP-C. Identification of multiple allelic variants associated with altered transport activity among European- and African-Americans"  JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 276, no. 38, 21 September 2001 (2001-09-21), pages 35669-35675, XP002306136 ISSN: 0021-9258 cited in the application	1,4-12, 15-21
A	Croed in the approaction	2,3,13,
	page 35672 - page 35673 figures 1-4 tables I-II abstract	14
A	US 2002/090622 A1 (DUDLEY ADAM JESTON ET AL) 11 July 2002 (2002-07-11) abstract paragraph '0075! - paragraph '0098! claims 1-12	1-21
<b>A</b>	NOZAWA TAKASHI ET AL: "Genetic polymorphisms of human organic anion transporters OATP-C (SLC21A6) and OATP-B (SLC21A9): Allele frequencies in the Japanese population and functional analysis" JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 302, no. 2, August 2002 (2002-08), pages 804-813, XP002306137 ISSN: 0022-3565 the whole document	1-21
A	TIRONA R G ET AL: "Pharmacogenomics of organic anion-transporting polypeptides (OATP)" ADVANCED DRUG DELIVERY REVIEWS, AMSTERDAM,	1-21
	NL, vol. 54, no. 10, 18 November 2002 (2002-11-18), pages 1343-1352, XP002245997 ISSN: 0169-409X the whole document	
	-/	
	*	

Inter II Application No PCT/GB2004/003236

		PCT/GB2004/003236
C.(Continu	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to dalm No.
A	IGEL M ET AL: "PHARMACOLOGY OF 3-HYDROXY-3-METHYLGLUTARYL-COENZYME A REDUCTASE INHIBITORS (STATINS), INCLUDING ROSUVASTATIN AND PITAVASTATIN" JOURNAL OF CLINICAL PHARMACOLOGY, LIPPINCOTT CO, HAGERSTOWN, MD, US, vol. 42, no. 8, August 2002 (2002-08), pages 835-845, XP008016576 ISSN: 0091-2700 cited in the application the whole document	1-21
A	KÖNIG J ET AL: "A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane." AMERICAN JOURNAL OF PHYSIOLOGY. GASTROINTESTINAL AND LIVER PHYSIOLOGY. JAN 2000, vol. 278, no. 1, January 2000 (2000-01), pages G156-G164, XP002191047 ISSN: 0193-1857 the whole document	1-21
Α	TAMAI I ET AL: "MOLECULAR IDENTIFICATION AND CHARACTERIZATION OF NOVEL MEMBERS OF THE HUMAN ORGANIC ANION TRANSPORTER (OATP) FAMILY" BIOCHIMICA ET BIOPHYSICA ACTA, AMSTERDAM, NL, vol. 273, no. 1, 2000, pages 251-260, XP000941538 ISSN: 0006-3002 cited in the application the whole document	1-21
A	JUNG DIANA ET AL: "Characterization of the human OATP-C (SLC21A6) gene promoter and regulation of liver-specific OATP genes by hepatocyte nuclear factor lalpha" JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 276, no. 40, 5 October 2001 (2001-10-05), pages 37206-37214, XP002306138 ISSN: 0021-9258 the whole document	1-21
A .	WEISS K M ET AL: "Linkage disequilibrium and the mapping of complex human traits" TRENDS IN GENETICS, ELSEVIER, AMSTERDAM, NL, vol. 18, no. 1, 1 January 2002 (2002-01-01), pages 19-24, XP004326531 ISSN: 0168-9525 the whole document	1-21

Inter al Application No PCT/GB2004/003236

	PCT/GB2004/003236					
C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT  Category * Citation of document, with indication, where appropriate of the relevant passanes  Relevant to claim No.						
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Heisvant to claim No.				
P,X	MWINYI JESSICA ET AL: "Evidence for inverse effects of OATP-C (SLC21A6) *5 and *1b haplotypes on pravastatin kinetics" CLINICAL PHARMACOLOGY & THERAPEUTICS, vol. 75, no. 5, May 2004 (2004-05), pages 415-421, XP002306139 ISSN: 0009-9236	1,4-12, 15-21				
P,A	cited in the application	2,3,13,				
	abstract	14				
Ρ,Χ	NIEMI MIKKO ET AL: "High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide—C (OATP-C, SLCO1B1)" PHARMACOGENETICS, vol. 14, no. 7, July 2004 (2004-07), pages 429-440, XP009039924 ISSN: 0960-314X	1,4-12, 15-21				
P,A	cited in the application	2,3,13,				
•••	abstract	14				
Ρ,Χ	KIM RICHARD B: "3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) and genetic variability (single nucleotide polymorphisms) in a hepatic drug uptake transporter: what's it all about?" CLINICAL PHARMACOLOGY AND THERAPEUTICS. MAY 2004, vol. 75, no. 5, May 2004 (2004-05), pages 381-385, XP009039939 ISSN: 0009-9236	1,4-12, 15-21				
Ρ,Α		2,3,13, 14				
	page 383					
<b>.</b>	ANONYMOUS: "OATP-C: SLC01B1" GENECARDS, 'Online! XP002317182 Retrieved from the Internet: URL:http://genecards.weizmann.ac.il/cgi-bi n/cards/carddisp?SLC01B1&search=oatp-c&suf f=txt> the whole document -& ANONYMOUS: "SNP linked to Gene (geneID: 10599)" SINGLE NUCLEOTIDE POLYMORPHISM, 'Online! XP002320267 Retrieved from the Internet: URL:http://www.ncbi.nlm.nih.gov/SNP//snp_r ef.cgi?locusId=10599>	1-21				
	-/					
	n/cards/carddisp?SLCO1B1&search=oatp-c&suf f=txt> the whole document -& ANONYMOUS: "SNP linked to Gene (geneID: 10599)" SINGLE NUCLEOTIDE POLYMORPHISM, 'Online! XPO02320267 Retrieved from the Internet: URL:http://www.ncbi.nlm.nih.gov/SNP//snp_r					

tnt al Application No
PCT/GB2004/003236

		PCT/GB2004/003236
	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	
Category •	Citation of document, with Indication, where appropriate, of the relevant passages	Relevant to claim No.
<b>A</b>	DATABASE EMBL 'Online! 15 March 2000 (2000-03-15), "Homo sapiens chromosome 11 clone RP11-484D2, WORKING DRAFT SEQUENCE, 22 unordered pieces." XP002317183 retrieved from EBI accession no. EM_PRO:AC025552	1-21
	Database accession no. ACO25552 the whole document	
<b>A</b>	CALAFELL F ET AL: "HAPLOTYPE EVOLUTION AND LINKAGE DISEQUILIBRIUM) A SIMULATION STUDY" HUMAN HEREDITY, KARGER, BASEL, CH, vol. 51, no. 1/2, October 2000 (2000-10), pages 85-96, XP001107179 ISSN: 0001-5652 the whole document	1-21
	STEPHENS J C ET AL: "Haplotype variation and linkage disequilibrium in 313 human genes" SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, US, vol. 293, no. 5529, 20 July 2001 (2001-07-20), pages 489-493, XP002213211 ISSN: 0036-8075 the whole document	1-21
	KRUGLYAK L: "Prospects for whole-genome linkage disequilibrium mapping of common disease genes" NATURE GENETICS, NATURE AMERICA, NEW YORK, US,	1-21
	vol. 22, June 1999 (1999-06), pages 139-144, XP002958585 ISSN: 1061-4036 the whole document	
	JORDE L B: "Linkage disequilibrium and the search for complex disease genes" GENOME RESEARCH, COLD SPRING HARBOR LABORATORY PRESS, US, vol. 10, no. 10, October 2000 (2000-10), pages 1435-1444, XP002224534 ISSN: 1088-9051 the whole document	1-21
	-/	

tritei si Application No
PCT/GB2004/003236

		PCT/GB2004/003236	1/003236		
C.(Continue	ation) DOCUMENTS CONSIDERED TO BE RELEVANT				
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.			
A	TOIVONEN H T T ET AL: "DATA MINING APPLIED TO LINKAGE DISEQUILIBRIUM MAPPING" AMERICAN JOURNAL OF HUMAN GENETICS, AMERICAN SOCIETY OF HUMAN GENETICS, CHICAGO, IL, US, vol. 67, no. 1, July 2000 (2000-07), pages 133-145, XP000995225 ISSN: 0002-9297 the whole document	1-21			
A	AKEY J ET AL: "Haplotypes vs single marker linkage disequilibrium tests: what do we do gain?" EUROPEAN JOURNAL OF HUMAN GENETICS, KARGER, BASEL, CH, vol. 9, no. 4, April 2001 (2001-04), pages 291-300, XP002964641 ISSN: 1018-4813 the whole document	1-21			
A	REICH D E ET AL: "LINKAGE DISEQUILIBRIUM IN THE HUMAN GENOME" NATURE, MACMILLAN JOURNALS LTD. LONDON, GB, vol. 411, no. 6834, 10 May 2001 (2001-05-10), pages 199-204, XP001026202 ISSN: 0028-0836 the whole document	1-21			
A	SHUANGLIN ZHANG ET AL: "Linkage disequilibrium mapping with genotype data" GENETIC EPIDEMIOLOGY, LISS, NEW YORK, NY,, US, vol. 22, 2002, pages 66-77, XP002903060 ISSN: 0741-0395 the whole document	1-21			
	3				
			•		
	·				

n......lonal application No.

PCT/GB2004/003236

Вох	No. I	N	ucleotide	and/or amin	o acid sequ	зепсе(в) (С	ontinua	tion of Item	1.b of the fir	st sheet)	•	
1.	With	regard ntion, th	to any nucl e internatio	eotide and/or a nal search wa	amino acid se s carried out o	quence disclo	sed in the	e international	application an	d necessary	to the claimed	
·	<b>a.</b>	type of	material a sequenc table(s) re	ce listing .	equence listing		٠	•				
	b.	format X	of material In written t		m							
	<b>c.</b>	time of	filed togeti	hing In the Internat her with the int subsequently t	emational app	plication in co	-		*	٠.		
2.		or fu	mished, the	required state	ements that th	e information	In the su	bsequent or a	and/or table re dditional copie e, were furnishe	s is identica	o has been filed to that in the	
3.	Additi	ional co	mments:									
					0¥0							
	•	•			•			•			•	
				-				*				

International application No. PCT/GB2004/003236

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)
This international Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
Claims Nos.:     because they relate to subject matter not required to be searched by this Authority, namely:
Ctaims Nos.:     because they relate to parts of the international Application that do not comply with the prescribed requirements to such an extent that no meaningful international Search can be carried out, specifically:
3. Light Nos.:  because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)
This International Searching Authority found multiple inventions in this international application, as follows:
see additional sheet
As all required additional search fees were timely paid by the applicant, this international Search Report covers all searchable claims.
As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. X As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
1, 3, 11-21 (completely); 2, 4-10 (partially) (inventions 1, 3 and 9)
4. No required additional search fees were timely paid by the applicant. Consequently, this international Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Remark on Protest
No protest accompanied the payment of additional search fees.

#### FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1, 4-12, 15-21 (partially)

Use of the Vall74Ala polymorphism in human OATP—C in statin therapy, based on an effect of said polymorphism on statin pharmacokinetics in humans.

2. claims: 1-10, 15-21 (partially)

Use of an allele of the -26A>G polymorphism of SEQ.ID.NO.2, which is in linkage disequilibrium with the Vall74Ala polymorphism, in human OATP-C in statin therapy, based on an effect of said polymorphism on statin pharmacokinetics in humans.

3. claims: 1-10, 15-21 (partially); 13-14 (completely)

Use of an allele of the -118A>C polymorphism of SEQ.ID.NO.2, which is in linkage disequilibrium with the Vall74Ala polymorphism, in human OATP-C in statin therapy, based on an effect of said polymorphism on statin pharmacokinetics in humans.

4. claims: 1-10, 15-21 (partially)

Use of an allele of the -309T>C polymorphism of SEQ.ID.NO.2, which is in linkage disequilibrium with the Vall74Ala polymorphism, in human OATP-C in statin therapy, based on an effect of said polymorphism on statin pharmacokinetics in humans.

5. claims: 1-10, 15-21 (partially)

Use of an allele of the -878A>G polymorphism of SEQ.ID.NO.2, which is in linkage disequilibrium with the Vall74Ala polymorphism, in human OATP-C in statin therapy, based on an effect of said polymorphism on statin pharmacokinetics in humans.

6. claims: 1-10, 15-21 (partially)

Use of an allele of the -903C>T polymorphism of SEQ.ID.NO.2, which is in linkage disequilibrium with the Vall74Ala polymorphism, in human OATP-C in statin therapy, based on an effect of said polymorphism on statin pharmacokinetics in humans.

#### FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

7. claims: 1-10, 15-21 (partially)

Use of an allele of the -1054G > T polymorphism of SEQ.ID.NO.2, which is in linkage disequilibrium with the Vall74Ala polymorphism, in human OATP-C in statin therapy, based on an effect of said polymorphism on statin pharmacokinetics in humans.

8. claims: 1-10, 15-21 (partially)

Use of an allele of the -1215T>A polymorphism of SEQ.ID.NO.2, which is in linkage disequilibrium with the Val174Ala polymorphism, in human OATP-C in statin therapy, based on an effect of said polymorphism on statin pharmacokinetics in humans.

9. claims: 1-10, 15-21 (partially)

Use of an allele of the -1558T>C polymorphism of SEQ.ID.NO.2, which is in linkage disequilibrium with the Vall74Ala polymorphism, in human OATP-C in statin therapy, based on an effect of said polymorphism on statin pharmacokinetics in humans.

10. claims: 1-10, 15-21 (partially)

Use of an allele of the T2122G polymorphism of SEQ.ID.NO.3, which is in linkage disequilibrium with the Val174Ala polymorphism, in human OATP-C in statin therapy, based on an effect of said polymorphism on statin pharmacokinetics in humans.

11. claims: 1-10, 15-21 (partially)

Use of an allele of the C2158T polymorphism of SEQ.ID.NO.3, which is in linkage disequilibrium with the Vall74Ala polymorphism, in human OATP-C in statin therapy, based on an effect of said polymorphism on statin pharmacokinetics in humans.

12. claims: 1-10, 15-21 (partially)

Use of an allele of the A2525C polymorphism of SEQ.ID.NO.3, which is in linkage disequilibrium with the Vall74Ala polymorphism, in human OATP-C in statin therapy, based on an effect of said polymorphism on statin pharmacokinetics in humans.

13. claims: 1-10, 15-21 (partially)

International Application No. PCT/GB2004 /003236

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Use of an allele of the G2651A polymorphism of SEQ.ID.NO.3, which is in linkage disequilibrium with the Val174Ala polymorphism, in human OATP-C in statin therapy, based on an effect of said polymorphism on statin pharmacokinetics in humans.

Information on patent family members

Inte \_\_nel Application No PCT/GB2004/003236

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
US 2002090622	A1	11-07-2002	US EP JP	2004235006 A1 1186672 A2 2002330758 A	25-11-2004 13-03-2002 19-11-2002